MedTrace Logo

Pioglitazone in Impaired Glucose Tolerance

NCT00306826 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2010-02-02

No results posted yet for this study

Summary

In patients with impaired glucose tolerance (IGT), the researchers want to study the relative effects of pioglitazone, simvastatin, or the combination of both on:

* intima media thickness (IMT) as an easily assessed marker of atherosclerosis
* heart rate variability (HRV) as a marker of autonomic neuropathy
* flow-mediated vasodilatation (FMD) of the brachial artery as a marker of endothelial function
* vascular and metabolic lab parameters

Conditions

  • Glucose Metabolism Disorders

Interventions

DRUG

pioglitazone

DRUG

simvastatin

DRUG

pioglitazone + simvastatin

Sponsors & Collaborators

  • Institut für Gesundheits- und Praxismanagement GmbH

    collaborator UNKNOWN

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Gerhard Schuler, MD · University of Leipzig

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2009-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306826 on ClinicalTrials.gov